ACHP Drug Cost Chart Pack The enclosed slides are free for public use DECEMBER 2015

The Spike in Drug Costs Advancements in pharmaceuticals can result in drugs that offer fewer side effects, improve a patient’s quality of life and save lives, but what if not everyone can afford them? THERE’S ENORMOUS PRESSURE ON….. Consumers and their families, who may be faced with the difficult choice between paying for MS medications and other necessities. Employers, who may be forced to make cuts to their overall benefits package in order to fund rising health care costs. Health care providers, who treat an increase in disease-related complications due in part to non-adherence to costly medications. Health plans and other payers, who want to ensure people get the right drugs and keep coverage affordable. Federal government, which is bearing an ever-growing share of the costs of these drugs, placing increasing pressure on the federal budget.

The Spike in Drug Costs: Diabetes GENERAL STATISTICS: 1 in 11 people in the U.S. has diagnosed or undiagnosed diabetes. This is expected to increase to 1 in 3 people by 2050. http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html http://www.cdc.gov/media/pressrel/2010/r101022.html http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf The cost of diagnosed diabetes in 2012 was $245 billion.

The Spike in Drug Costs: Diabetes Primarily because of escalating drug costs, spending on insulin and other diabetes medications is expected to rise 18.3 percent over the next three years, a rate of increase 60 times greater than the recent income growth average of just 0.3 percent across all households. http://lab.express-scripts.com/drug-trend-report/ http://www.census.gov/newsroom/press-releases/2014/cb14-169.html

The Spike in Drug Costs: Diabetes Diabetes Drugs with Significant Percent Price Changes Over Five Years (3/1/2010 – 2/28/2015) Januvia Oral Tablet, Bottle of 100 (25MG, 50MG, or 100MG) Humalog Mix Subcutaneous Suspension 100 UNIT/ML, 10ML vial of suspension (50/50 mix or 75/25 mix) Novolin 70/30 Subcutaneous Suspension (70-30) 100 UNIT/ML, 10 ML vial of suspension; Novolin N Subcutaneous Suspension 100 UNIT/ML, 10 ML vial of suspension; and Novolin R Injection Solution 100 UNIT/ML, 10 ML vial of solution Levemir Subcutaneous Solution 100 UNIT/ML, 10 ML of solution Lantus Subcutaneous Solution 100 UNIT/ML, 10 ML of solution SymlinPen 60 Subcutaneous Solution Pen-injector 1500 MCG/1.5ML, 2 pens with 1.5 ML of solution Humulin R U-500 (concentrated) Subcutaneous Solution 500 UNIT/ML, 20 ML of solution Source: Medi-Span® Price Rx®. Figures reflect wholesale acquisition cost. Note: Price modifications will alter the values reflected above.

The Spike in Drug Costs: Multiple Sclerosis GENERAL STATISTICS: Multiple Sclerosis (MS) affects at least 400,000 people in the United States and more than 2.5 million globally. MS drugs help people manage their condition and enhance their comfort and quality of life. Pietrangelo, A., & Higuera, V. (2015, March 24). Multiple sclerosis by the numbers: facts, statistics, and you. Retrieved from http://www.healthline.com/health/multiplesclerosis/ facts-statistics-infographic Medications. (n.d.). Retrieved from http://www. nationalmssociety.org/Treating-MS/Medications The cost of taking MS drugs can span a lifetime. There is currently no cure for MS.

The Spike in Drug Costs: Multiple Sclerosis Walker, J. (2015, November 15). Sanofi’s Genzyme gets FDA approval for MS drug. Retrieved from http://www.wsj. com/articles/sanofis-genzyme-gets-fda-approval-for-msdrug- 1416049878 Lemtrada, approved for sale in the U.S. in 2014, has a two-year course of treatment estimated at $158,000.

The Spike in Drug Costs: Multiple Sclerosis MS Drugs with the Highest % Price Changes Since Launch for a 30-Day Supply *Date listed is the first instance of available pricing data in Medi-Span® Price Rx®. The true launch date is earlier than that listed. Note: Price modifications will alter the values reflected above. Source: Medi-Span® Price Rx® and www.rxlist.com. Figures reflect wholesale acquisition cost. Medi-Span® Price Rx®. (2015). Retrieved from https:// pricerx.medispan.com. (Pricing is for 40MG/ML dose and a quantity of 12 syringes. Manufacturer-recommended dosing is 3X/week.) *Date listed is the first instance of available pricing data in Medi-Span® Price Rx®. The true launch date is earlier than that listed. Source: Medi-Span® Price Rx® and www.rxlist.com. Figures reflect wholesale acquisition cost. Note: Price modifications will alter the values reflected above.

The Spike in Drug Costs: Multiple Sclerosis First-generation MS drugs, originally costing $8,000 - $11,000 per year, can now exceed $60,000 per person per year. Hartung, D., Bourdette, D., Ahmed, S., & Whitman, R. (2015). The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology, 10(1212), 1727-1728. http:/ / dx. doi. org/ 10. 1212/ WNL. 0000000000001608

The Spike in Drug Costs: Multiple Sclerosis Hartung, D., Bourdette, D., Ahmed, S., & Whitman, R. (2015). The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology, 10(1212), 1727-1728. http:/ / dx. doi. org/ 10. 1212/ WNL. 0000000000001608

The Spike in Drug Costs: Multiple Sclerosis The new 40 mg dose of the widely prescribed drug Copaxone costs $5,008 a month, yet shows no gain in efficacy over the 20 mg dose. Comi, G., Cohen, J., Arnold, D., Wynn, D., & Filippi, M. (2011). Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology, 69(1), 75-82. doi:10.1002/ana.22316

The Spike in Drug Costs: Rheumatoid Arthritis GENERAL STATISTICS: Vandever, L. (2014). Rheumatoid Arthritis by the Numbers: Facts, Statistics, and You. Retrieved from http://www.healthline.com/health/rheumatoid-arthritis/facts-statisticsinfographic Yazdany, J., Dudley, R.A., Chen, R., Lin, G.A., & Tseng, C. (2015). Coverage for High-Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D. Arthritis & Rheumatology, volume 67 (6), 1474-1480. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/art.39079/abstract About 1.3 million Americans have rheumatoid arthritis (RA) and this number is forecast to reach 1.68 million by 2020.

The Spike in Drug Costs: Rheumatoid Arthritis The $1 million dollar estimate is based on the wholesale acquisition cost for a 30-day supply of Enbrel, Humira or Xeljanz in Medi-Span® Price Rx®, multiplied by treatment duration. Treatment duration is standardized to 30-day increments after subtracting the average age of diagnosis (45 years) from the average life expectancy of people with RA (Male: 69.4 years, Female: 78.2 years), which is based on data from the Centers for Disease Control and Prevention (CDC) and the Johns Hopkins Arthritis Center. This estimate does not take into account any rebates, discounts or insurance arrangements. The cost of taking RA drugs can exceed $1 million over the course of an individual’s lifetime.

The Spike in Drug Costs: Rheumatoid Arthritis Vandever, L. (2014). Rheumatoid Arthritis by the Numbers: Facts, Statistics, and You. Retrieved from http://www.healthline.com/health/rheumatoid-arthritis/facts-statisticsinfographic Sixty percent of people with inadequately treated RA are unable to work 10 years after onset.

The Spike in Drug Costs: Rheumatoid Arthritis RA Drug Prices for 30-Day Supply, 2013-2016 Note: Price modifications will alter the values reflected above. Source: Medi-Span® Price Rx®. Figures reflect wholesale acquisition cost.

The Spike in Drug Costs: Rheumatoid Arthritis Yazdany, J., Dudley, R.A., Chen, R., Lin, G.A., & Tseng, C. (2015). Coverage for High-Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D. Arthritis & Rheumatology, volume 67 (6), 1474-1480. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/art.39079/abstract The cost of treating RA in the U.S. will increase from $6.4 billion in 2013 to $9.3 billion by 2020.

The Spike in Drug Costs: LDL Cholesterol

The Spike in Drug Costs: LDL Cholesterol

The Spike in Drug Costs: LDL Cholesterol